KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC.

Naoto T Ueno, Francesco Cottone, Kyle Dunton, William Jacot, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Aleix Prat, Junji Tsurutani, Yeon Hee Park, Hope S Rugo, Binghe Xu, Fatima Cardoso, Zahi Mitri, Reshma Mahtani, Cecilia Orbegoso Aguilar, Feng Xiao, Nadia Harbeck, David A Cameron, Shanu Modi

Oncologist 30(5) oyaf048

PMID40349139
PMCIDPMC12065936
DOI10.1093/oncolo/oyaf048
发表日期2025-05-11
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

BACKGROUND: The phase 3 DESTINY-Breast04 trial demonstrated superior efficacy and acceptable safety with trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy in previously treated patients with human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). We report the patient-reported outcomes (PROs), focusing on the hormone receptor-positive cohort. PATIENTS AND METHODS: Patients were randomized 2:1 to T-DXd (5.4 mg/kg intravenously every 3 weeks) or physician's choice of chemotherapy and prospectively assessed for PRO measures. Change from baseline and time to definitive deterioration (TDD) were calculated from the EORTC QLQ-C30 and QLQ-BR45 and the EQ-5D-5L questionnaires. RESULTS: Baseline global health status/quality of life (GHS/QoL) scores were similar between groups (T-DXd, 331 patients; physician's choice, 163 patients); there were no clinically meaningful changes while on either treatment (median duration: T-DXd, 8.2 months; physician's choice, 3.5 months). Median TDD for GHS/QoL was delayed with T-DXd vs physician's choice (11.4 vs 7.5 months, respectively; hazard ratio, 0.69; 95% CI, 0.52-0.92). Median TDD for all prespecified PROs, including pain, favored T-DXd. In an additional analysis, the median TDD was shorter for nausea and vomiting with T-DXd vs the physician's choice. CONCLUSIONS: Trastuzumab deruxtecan maintained GHS/QoL scores despite a longer treatment course compared with standard chemotherapy and delayed definitive deterioration across all prespecified PROs vs the physician's choice. Appropriate management of adverse events and use of preventive measures (ie, antiemetic prophylaxis) may further support patient health-related quality of life. These findings reinforce the benefit of T-DXd as an option for patients with HER2-low mBC. ClinicalTrials.gov: NCT03734029.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 3

Figure 3. Kaplan-Meier plot of time to definitive deterioration of (A) GHS/QoL, (B) pain, and (C) physical functioning with T-DXd and physician’s choice of chemotherapy in the HR+ cohort. EORTC, European Organization for Research and Treatment of Cancer; GHS, global health status; physician’s choice, physician’s choice of chemotherapy; PRO, patient-reported outcome; QLQ-C30, Quality of Life Core 30 questionnaire; QoL, quality of life; TDD, time to definitive deterioration; T-DXd, trastuzumab deruxtecan. GHS/QoL, pain symptoms, and physical functioning are scales of the EORTC QLQ-C30. Clinically meaningful definitive deterioration was defined as a change of ≥ 10 points from baseline at either 2 or more consecutive time points, last PRO assessment, or death by the first survival follow-up visit. a Nominal P value not adjusted for multiple testing. b All patients were included in the analysis; patients without baseline assessments were censored per the statistical analysis plan.

A

time to definitive deterioration of GHS/QoL

Figure 3 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:extreme jump曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
B

time to definitive deterioration of pain

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump曲线 2:extreme upward reversal
查看结果
C

time to definitive deterioration of physical functioning

Figure 3 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:extreme jump曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. GHS/QoL change from baseline with T-DXd and physician’s choice of chemotherapy over time in the HR+ cohort. C, cycle; CFB, change from baseline; EORTC, European Organization for Research and Treatment of Cancer; GHS, global health status; HR, hormone receptor; physician’s choice, physician’s choice of chemotherapy; QLQ-C30, Quality of Life Core 30 questionnaire; QoL, quality of life; T-DXd, trastuzumab deruxtecan. HR+ status was based on interactive voice-response system data at the time of randomization. GHS/QoL score is from the EORTC QLQ-C30. Scores range from 0 to 100; a higher score represents higher (“better”) GHS/QoL. Data between T-DXd and physician’s choice treatment groups are only interpretable through cycle 13 (after which the number of patients with available change from baseline data fell below 10% in the physician’s choice group). Data in the T-DXd treatment group are interpretable through cycle 27 (after which the number of patients with available change from baseline data fell below 10%). a On day 1 of cycle.
非 KM Figure
Figure 2Figure 2. Forest plot of time to definitive deterioration in PRO measures of interest with T-DXd and physician’s choice of chemotherapy in the HR+ cohort. EORTC, European Organization for Research and Treatment of Cancer; EQ-5D-5L, EuroQol 5-dimension, 5-level questionnaire; GHS, global health status; HR, hormone receptor; NE, not estimable; physician’s choice, physician’s choice of chemotherapy; PRO, patient-reported outcome; QLQ-BR45, Quality of Life Breast cancer questionnaire; QLQ-C30, Quality of Life Core 30 questionnaire; QoL, quality of life; TDD, time to definitive deterioration; T-DXd, trastuzumab deruxtecan; VAS, visual analog scale. HR+ status was based on interactive voice-response system data at the time of randomization. Clinically meaningful definitive deterioration was defined as a change of ≥ 10 points from baseline, at either 2 or more consecutive time points, last PRO assessment, or death by the first survival follow-up visit. a Primary PRO variable of interest. b Secondary PRO variable of interest. c TDD of fatigue, nausea/vomiting, and EQ-5D-5L VAS were additional analyses. d Scored using the EORTC QLQ-BR23 algorithm. e Nominal P value not adjusted for multiple testing.
非 KM Figure
Figure 4Figure 4. Nausea and vomiting change from baseline with T-DXd and physician’s choice of chemotherapy over time in the HR+ cohort. C, cycle; CFB, change from baseline; EORTC, European Organization for Research and Treatment of Cancer; physician’s choice, physician’s choice of chemotherapy; QLQ-C30, Quality of Life Core 30 questionnaire; T-DXd, trastuzumab deruxtecan. Nausea and vomiting is a score from the EORTC QLQ-C30. Scores range from 0 to 100; a higher score represents higher (“worse”) symptomology. Data between T-DXd and physician’s choice treatment groups are only interpretable through cycle 13 (after which the number of patients with available change from baseline data fell below 10% in the physician’s choice group). Data in the T-DXd treatment group are interpretable through cycle 27 (after which the number of patients with available change from baseline data fell below 10%). a On day 1 of cycle.
非 KM Figure